Strumento inattivo

Altre lingue Zynerba Pharmaceuticals, Inc.

Azioni

ZYNE

US98986X1090

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE - Zynerba	12/10/23
Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from NASDAQ Composite Index	12/10/23
Harmony Biosciences Holdings Completes Acquisition of Zynerba Pharmaceuticals	11/10/23
Zynerba Pharmaceuticals : Acquisition/Asset Disposal - Form 8-K	11/10/23
HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE	11/10/23
Fragile X Syndrome Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)	10/10/23
Harmony Biosciences Holdings, Inc. completed the acquisition of Zynerba Pharmaceuticals, Inc..	10/10/23
Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions - Zynerba	05/10/23
Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions	04/10/23
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares before 5:00 PM New York City Time, on Tuesday October 10, 2023	02/10/23
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023 - Zynerba	29/09/23
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023	29/09/23
Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from S&P TMI Index	28/09/23
Harmony Biosciences Says its Xylophone Acquisition Unit Extends Tender Offer for Zynerba Pharmaceuticals to Oct. 10	27/09/23
HARMONY BIOSCIENCES ANNOUNCES EXTENSION OF TENDER OFFER TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.	27/09/23
Fragile X Syndrome Pipeline, Clinical Trials and NDA Approvals 2023 (Updated)	18/09/23
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium	14/09/23
ZYNERBA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Zynerba Pharmaceuticals, Inc. - ZYNE	05/09/23
Shareholder Alert: Ademi LLP investigates whether Zynerba Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Harmony	28/08/23
Thinking about buying stock in Zynerba Pharmaceuticals, Taysha Gene Therapies, Novo Integrated Sciences, Design Therapeutics, or Limbach Holdings?	17/08/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Zynerba Pharmaceuticals, Inc.

Azioni

ZYNE

US98986X1090

Altre lingue

Filtri